IL23A and psoriasis: We evaluated the effect of methotrexate and biologics targeting tumour necrosis factor, interleukin (IL)-17, and IL-23 on humoral (serological and functional) and cellular immune responses to the second dose of the COVID-19 vaccine BNT162b2 in individuals with psoriasis.